help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barone, R. M.
Right arrow Articles by Judd, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barone, R. M.
Right arrow Articles by Judd, H. L.

Journal of Clinical Endocrinology & Metabolism, Vol 49, 672-676, Copyright © 1979 by Endocrine Society

ARTICLES

Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone

RM Barone, IM Shamonki, PK Siiteri and HL Judd

To determine if delta 1-testololactone can inhibit the peripheral aromatization of androstenedione (delta), nine postmenopausal women with metastatic breast cancer were studied before and after 2 weeks of therapy with 250 mg of the drug, given every 6 h by mouth. The conversion ratio of delta to estrone (E1) was significantly reduced (P less than 0.005) from a mean (+/-SE) of 0.0098 +/- 0.0025 before to 0.0009 +/- 0.0005 after treatment. The drug's effect on the metabolism of delta seemed to be specific since significant changes in the MCR of delta and in the conversion ratio to testosterone were not observed. That this inhibition of peripheral aromatization had an effect on E1 metabolism was shown by the significant decrease (P less than 0.01) of mean serum E1 levels from 22 +/- 3 pg/ml before to 12 +/- 1 pg/ml after treatment. Serum estradiol levels rose slightly from 8 +/- 0.8 to 12 +/- 4 pg/ml. Serum delta and testosterone levels were unchanged by therapy. These data are consistent with the concept that delta 1-testololactone is a potent inhibitor of peripheral aromatization of delta to E1. This mechanism could explain the antitumor properties of this compound.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
R H Straub, L B Tanko, C Christiansen, P J Larsen, and D S Jessop
Higher physical activity is associated with increased androgens, low interleukin 6 and less aortic calcification in peripheral obese elderly women
J. Endocrinol., October 1, 2008; 199(1): 61 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Geisler and P. E. Lonning
Aromatase Inhibition: Translation into a Successful Therapeutic Approach
Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Janinis, M. Patriki, L. Vini, G. Aravantinos, and J. S. Whelan
The pharmacological treatment of aggressive fibromatosis: a systematic review
Ann. Onc., February 1, 2003; 14(2): 181 - 190.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1979 by The Endocrine Society